evidencegaps
Primary study · included by 1 review

The effect of Hangeshashinto on Oral Mucositis Caused by Induction Chemotherapy in Patients with Head and Neck Cancer.

Taira 2020 · Taira Kenkichiro, Fujiwara Kazunori, Fukuhara Takahiro, et al. · Yonago acta medica · 2020

Included by

Hangeshashinto for the prevention of oral mucositis in patients receiving chemotherapy: a systematic review and meta-analysis.
Non-Cochrane · intervention · 2026 · cited as Taira 2020 · Table 1; Table 4; reference list
Outcome this study informsPooled effectEvidenceCertainty
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1)
Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo
RR 0.86 [0.73, 1.00]6 studies · 293 participantsModerate
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1)
Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo
RR 0.90 [0.67, 1.21]4 studiesGRADE not reported
Chemotherapy-induced oral mucositis (grade 2 or higher by CTCAE v5.0, described as more than grade 1)
Hangeshashinto (TJ-14) during chemotherapy vs No hangeshashinto or placebo
RR 0.81 [0.56, 1.17]2 studiesGRADE not reported

1 including review in total.